Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $34.92 in the prior trading day, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $34.96, up 0.11%. In other words, the price has increased by $0.11 from its previous closing price. On the day, 1.07 million shares were traded. IONS stock price reached its highest trading level at $35.7 during the session, while it also had its lowest trading level at $34.88.
Ratios:
Our goal is to gain a better understanding of IONS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.82 and its Current Ratio is at 8.91. In the meantime, Its Debt-to-Equity ratio is 3.00 whereas as Long-Term Debt/Eq ratio is at 2.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on August 02, 2024, Downgraded its rating to Market Perform and sets its target price to $60 from $67 previously.
On July 24, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $53 to $62.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 23 ’24 when Hayden Michael R bought 5,000 shares for $36.22 per share. The transaction valued at 181,079 led to the insider holds 35,219 shares of the business.
Swayze Eric sold 1,194 shares of IONS for $45,278 on Nov 12 ’24. The EVP Research now owns 33,713 shares after completing the transaction at $37.92 per share. On Nov 12 ’24, another insider, Monia Brett P, who serves as the Chief Executive Officer of the company, sold 6,630 shares for $38.05 each. As a result, the insider received 252,294 and left with 167,393 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 5520078848 and an Enterprise Value of 5023904256. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.88 while its Price-to-Book (P/B) ratio in mrq is 8.33. Its current Enterprise Value per Revenue stands at 6.256 whereas that against EBITDA is -14.94.
Stock Price History:
Over the past 52 weeks, IONS has reached a high of $54.44, while it has fallen to a 52-week low of $33.33. The 50-Day Moving Average of the stock is -5.72%, while the 200-Day Moving Average is calculated to be -16.19%.
Shares Statistics:
The stock has traded on average 1.43M shares per day over the past 3-months and 1561510 shares per day over the last 10 days, according to various share statistics. A total of 157.81M shares are outstanding, with a floating share count of 145.55M. Insiders hold about 7.82% of the company’s shares, while institutions hold 98.05% stake in the company. Shares short for IONS as of 1734048000 were 10528956 with a Short Ratio of 7.35, compared to 1731628800 on 11050361. Therefore, it implies a Short% of Shares Outstanding of 10528956 and a Short% of Float of 7.7800006.
